Barbara Sleight
Overview
Explore the profile of Barbara Sleight including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
791
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pennesi E, Brivio E, Ammerlaan A, Jiang Y, van der Velden V, Beverloo H, et al.
Haematologica
. 2024 Jan;
109(10):3157-3166.
PMID: 38186333
Inotuzumab ozogamicin (InO) is a CD22-directed antibody conjugated with calicheamicin. The phase IB of the ITCC-059 trial tested InO combined with chemotherapy in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL)....
2.
Pennesi E, Michels N, Brivio E, van der Velden V, Jiang Y, Thano A, et al.
Leukemia
. 2022 Apr;
36(6):1516-1524.
PMID: 35468945
Inotuzumab Ozogamicin is a CD22-directed antibody conjugated to calicheamicin, approved in adults with relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (BCP-ALL). Patients aged 1-18 years, with R/R CD22 ...
3.
Kantarjian H, Stock W, Cassaday R, DeAngelo D, Jabbour E, OBrien S, et al.
Clin Cancer Res
. 2021 Feb;
27(10):2742-2754.
PMID: 33602684
Purpose: We assessed the relationship between cluster of differentiation-22 (CD22) expression and outcomes of inotuzumab ozogamicin versus standard of care (SC) in INO-VATE (NCT01564784). Patients And Methods: Adults with relapsed/refractory...
4.
Brivio E, Locatelli F, Lopez-Yurda M, Malone A, Diaz-de-Heredia C, Bielorai B, et al.
Blood
. 2020 Oct;
137(12):1582-1590.
PMID: 33067614
This phase 1 study investigated the recommended phase 2 dose (RP2D) of inotuzumab ozogamicin (InO), a CD22-directed antibody-drug conjugate, in pediatric patients with multiple relapsed/refractory (R/R) CD22+ acute lymphoblastic leukemia...
5.
Fujishima N, Uchida T, Onishi Y, Jung C, Goh Y, Ando K, et al.
Int J Hematol
. 2019 Oct;
110(6):709-722.
PMID: 31655984
Inotuzumab ozogamicin (InO) is a targeted treatment for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). InO was previously studied in INO-VATE, an international, open-label, randomized phase 3...
6.
Cortes J, Dombret H, Merchant A, Tauchi T, DiRienzo C, Sleight B, et al.
Future Oncol
. 2019 Sep;
15(31):3531-3545.
PMID: 31516032
Glasdegib, an oral Hedgehog pathway inhibitor, has been associated with significantly improved survival when combined with low-dose cytarabine in patients with untreated acute myeloid leukemia (AML) who were unsuitable for...
7.
Kantarjian H, DeAngelo D, Stelljes M, Liedtke M, Stock W, Gokbuget N, et al.
Cancer
. 2019 Mar;
125(14):2474-2487.
PMID: 30920645
Background: Inotuzumab ozogamicin (InO) is an antibody-drug conjugate used for adults with relapsed/refractory B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). The INotuzumab Ozogamicin trial to inVestigAte Tolerability and Efficacy (INO-VATE)...
8.
Jabbour E, Advani A, Stelljes M, Stock W, Liedtke M, Gokbuget N, et al.
Am J Hematol
. 2019 Jan;
94(4):408-416.
PMID: 30623490
Karyotype is frequently used to predict response and outcome in leukemia. This post hoc exploratory analysis evaluated the relationship between baseline cytogenetics and outcome in patients with relapsed/refractory acute lymphoblastic...
9.
Jabbour E, DeAngelo D, Stelljes M, Stock W, Liedtke M, Gokbuget N, et al.
Cancer
. 2018 Jan;
124(8):1722-1732.
PMID: 29381191
Background: Inotuzumab ozogamicin (InO) has demonstrated efficacy and tolerability in patients aged 18 to 78 years with relapsed/refractory acute lymphoblastic leukemia (ALL) in the INO-VATE trial. This subset analysis compared...
10.
Kantarjian H, DeAngelo D, Stelljes M, Martinelli G, Liedtke M, Stock W, et al.
N Engl J Med
. 2016 Jun;
375(8):740-53.
PMID: 27292104
Background: The prognosis for adults with relapsed acute lymphoblastic leukemia is poor. We sought to determine whether inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, results in better outcomes in...